Comparison Between Whole-Body MRI and PET/CT in Pediatric Oncology

Open access

Summary

Introduction. Positron emission tomography/computer tomography (PET/CT) is one of the main imaging tests for solid tumor and metastases diagnostic nowadays. However, PET/CT scanning is related to the risk of ionizing radiation exposure, which is especially harmful for children health. Whole-body MRI (WB-MRI) allows exact evaluation of malignant tumor without the radiation exposure.

Aim of the Study.To compare and evaluate informativity of WB-MRI and PET/CT imaging methods for detection of metastases in children with malignant disease, being treated at Children’s Clinical University Hospital, Riga, Latvia. The gained data were also compared to the world data published before.

Material and methods. This retrospective study included all patients in whom both PET/CT and WB-MRI imaging examinations were performed between July 2016 and February 2017 in Latvia. Inclusion criteria were: age under 18 years, histological confirmation of a malignant disease. The study included 10 patients (7 males, 3 females, mean age 11 years 7 months). Two patients underwent both examinations 3 times, resulting in a total of 14 cases.

Results. There were identified three types of tumor: Hodgkin lymphoma (n = 12), non-Hodgkin lymphoma (n = 1), rhabdomyosarcoma (n = 1).

PET/CT mean radiation exposure was 263,2 [95% CI: 202.27 - 324.12] mGy.cm, mean radiotracer dosage was 143,5 [95% CI: 114. - 172.52] MBq.

There were identified 34 lesions: 24 (70%) lymph nodes, 5 (15%) bone lesions, 5 (15%) soft tissue lesions. 21 malignant lesions were detected by PET/CT. 27 lesions were found by WB-MRI. Out of 34 lesions, eighteen were identified by both imaging methods. Both examinations found absence of residual disease in 2 cases.

Eleven lesions were detected by WB-MRI (7 lymph nodes, 1 bone lesion and 3 soft tissue lesions) that were not identified by PET/ CT. 5 lesions could not be identified by WB-MRI (2 lymph nodes, 1 bone lesion and 2 soft tissue lesions) that were detected by PET/CT imaging method.

Conclusions. WB-MRI examination should be used before and in addition to PET/CT imagining in children with oncological disease. PET/CT examination results interpretation should be done based on WB-MRI imaging results. WB-MRI could not completely replace PET/CT imaging.

1. Antoch G., Vogt FM., Freudenberg LS. et al. Wholebody dual-modality PET/CT and whole-body MRI for tumor staging in oncology // JAMA, 2003; 290:3199–206

2. Brennan D. D., Gleeson T, Coate LE, et al. A comparison of whole-body MRI and CT for the staging of lymphoma //AJR Am J Roentgenlogy, 2005;185(3):711—6

3. Canale S., Vilcot L., Ammari S. et al. Whole body MRI in pediatric oncology // Diagnostic and Interventional Imaging, 2014; 95, 541—550

4. Chawla S. C., et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: a 5-year retrospective review // Pediatric Radiology, 2010 May; 40(5): 681–686

5. Chen Z., Li X., Fang Li, et al. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics // European Journal of Radiology, 2010; 75: 329–335

6. Ciliberto M. et al. Comparison between wholebody MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review // Radiology and Oncology, 2013 Sep; 47(3): 206–218

7. CureSearch for childrens cancer – [viewed 28.12.2016.]. Accessed: http://curesearch.org/

8. ESMO 2016 Press Release: High response rate in phase I/II paediatric brain cancer trial sets stage for combination therapy with higher response and lower toxicity. October, 2016 – [viewed 06.03.2017.]. Accessed: http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/High-response-rate-in-phase-I-II-paediatric-brain-cancer-trial-sets-stage-for-combination-therapy-with-higher-response-and-lower-toxicity

9. Heindel W., Gübitz R., Vieth V., et al. The Diagnostic Imaging of Bone Metastases // Deutsches Ärzteblatt International, 2014;111(44):741-747

10. Klenk C., Gawande R., Uslu L. et al. Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, nonrandomised, single-centre study // Lancet Oncology, 2014; 15: 275–85

11. Krohmer S., Sorge I., Krausse A. et al. Whole-body MRI for primary evaluation of malignant disease in children // European Journal of Radiology, 2010; 74: 256–261

12. Kumar J., Seith A., Kumar A., et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT //Pediatric Radiology, 2008;38(9):953—62

13. Punwani S., Taylor SA., Bainbridge A., et al. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging withan enhanced PET/CT reference for initial staging // Radiology, 2010;255(1):182—90

14. Robbins E. Radiation risks from imaging studies in children with cancer // Pediatric Blood Cancer, 2008; 51: 453–57

15. Schmidt GP, Baur-Melnyk A, Herzog P, et al. Highresolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomographycomputed tomography: experience on a 32-channel system // Investigative Radiology, 2005;40:743–53

16. Vandevoorde C. CT Protocols and CT Dose Contribution in PET/CT // iPET 2011 – Parallel Session IIIc, Panel Discussion: Practical Aspects of CT

Acta Chirurgica Latviensis

The Journal of Riga Stradins University; Latvian Association of Surgeons; Latvian Association of Paediatric Surgeons

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 60 60 15
PDF Downloads 44 44 3